LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Anavex Life Sciences Corp

Gesloten

SectorGezondheidszorg

8.01 -2.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.96

Max

8.05

Belangrijke statistieken

By Trading Economics

Inkomsten

915K

-11M

EPS

-0.132

Werknemers

42

EBITDA

-779K

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+254.92% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-21M

706M

Vorige openingsprijs

10.21

Vorige sluitingsprijs

8.01

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jun 2025, 22:33 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefonica Ecuador for $380 Million

14 jun 2025, 01:24 UTC

Acquisities, Fusies, Overnames

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 jun 2025, 23:50 UTC

Acquisities, Fusies, Overnames

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 jun 2025, 23:20 UTC

Acquisities, Fusies, Overnames

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 jun 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 jun 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 jun 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefonica Ecuador for $380M

13 jun 2025, 22:04 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 jun 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Bunge: Outside Date Extended to July 3

13 jun 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 jun 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Bunge Gets Mexico Approval for Viterra Deal

13 jun 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Bunge Gets China Approval for Viterra Deal

13 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 jun 2025, 20:45 UTC

Acquisities, Fusies, Overnames

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 jun 2025, 19:30 UTC

Marktinformatie

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 jun 2025, 19:12 UTC

Marktinformatie

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 jun 2025, 19:04 UTC

Marktinformatie

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 jun 2025, 18:54 UTC

Marktinformatie

Correction to Gold Settles Market Talk

13 jun 2025, 18:01 UTC

Marktinformatie

Gold Settles at Record High -- Market Talk

13 jun 2025, 17:40 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 jun 2025, 17:21 UTC

Marktinformatie

Dollar Index, Commodities Rise -- Market Talk

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Peer Vergelijking

Prijswijziging

Anavex Life Sciences Corp Prognose

Koersdoel

By TipRanks

254.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.5 USD  254.92%

Hoogste 42 USD

Laagste 15 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Anavex Life Sciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

8.275 / 9.312Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.